{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "4019c56c167102519d2393b25a5fb7b9",
    "title": "Notes From the Road: Bioprocessing Summit 2025 in Boston Edition",
    "source_uri": "2025-08-28/U.S. Life Science Diagnostic Tools Notes From the Road Bioprocessing Summit 2025 in Boston EditionU.S. Life Science Diag_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T10:40:24.369460",
      "extracted_at": "2025-10-26T10:40:24.369468"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 24,
        "successful_pages": 24,
        "date": "2025-08-28",
        "publication": "2025-08-28",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 5,
          "removed_paragraphs": 22,
          "reduction_ratio": 0.3489401184783385
        },
        "input_relative_path": "2025-08-28"
      }
    }
  },
  "passages": [
    {
      "passage_id": "a2828c692edf47a1",
      "text": "U.S. Life Science & Diagnostic Tools",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "568894b29b4bb327",
      "text": "Last week at the Bioprocessing Summit in Boston, we toured the exhibition hall and attended presentations and panel discussions on the latest industry challenges and opportunities, particularly in the CGT market.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "351208c1bb5253e5",
      "text": "Last week in Boston, we attended the 2025 Bioprocessing Summit to dig into the latest industry dynamics following a volatile earnings season that raised investor concerns particularly around the demand outlook for cell and gene therapies (CGT). Please see below our key takes from the exhibit hall, in addition to the keys and notes from the presentations and panels we attended.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8d9de1a09d397e8b",
      "text": "CGT demand under pressure in the NT, but plenty of excitement about the LT",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cf8447ce1dc13a3a",
      "text": "- NT demand expected to remain soft",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "edab40a24257bfe5",
      "text": "- Overall, CDMOs and tools providers noted CGT demand is sluggish, weighed down by incremental risk-off sponsor and investor behavior",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c4dc7f8b31d2c039",
      "text": "- Sponsors are prioritizing their lead target (often mAbs/ADCs) instead of taking shots on goal in higher risk and higher cost CGT assets",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ed5768eb75b1f5e3",
      "text": "- VC funding was already soft and negative headlines and heightened regulatory uncertainty make raises more challenging",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d8d8863421e996cd",
      "text": "- Negative headlines around patient deaths, commercial drugs pulled because too costly, regulatory uncertainty, layoffs and facility closures all contribute to deteriorating NT sentiment",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "504b32eb182344c1",
      "text": "- Digging in on advanced modalities:",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d54cb5f65f55ab7c",
      "text": "- Digging in on advanced modalities: - RAV - the most under pressure of the group. Toxicity volatility has always been a problem and patient deaths have raised caution here. AAV also faces challenges with high commercial price tags and payer friction. Nonetheless, AAV brings durability without chromosomal integration, enabling multi-yr expression, and thus an attractive vector.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7393157c1f0f5932",
      "text": "Please see analyst certifications and important disclosures beginning on page 22. Completed: 28- Aug- 25, 00:27 GMT Released: 28- Aug- 25, 10:00 GMT Restricted - External",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ac814bc44b8fb7cf",
      "text": "U.S. Life Science & Diagnostic Tools NEUTRAL Unchanged",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c9c17ce6d9505f99",
      "text": "- mRNA - demand reset lower post-COVID and pressured by HHS move away from mRNA R&D- RNAi - healthy demand supported by broadening indications and payer familiarity- Autologous & Allogeneic CAR-T - Solid demand overall, though allogeneic data momentum continues but recent safety events slightly pressure sentiment. Autologous has been stronger as multiple are on market with many more entering later-phase trials",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f111423e4d6d2659",
      "text": "- LT growth intact and set to benefit from technological innovation, regulatory clarity, and CMC (chemistry, mfg., and control) standardization",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f3d773fbf18bf920",
      "text": "- Advances in process intensification, continuous manufacturing, and smaller footprints cited as differentiators that will unlock cost efficiencies. Technological advancements are generating positive datapoints and helping address key challenges, but are launching in a tough macro. GT costs should benefit from trend towards in-vivo delivery platforms as well",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1a588ca6fd7167c5",
      "text": "- many challenges are solvable but momentum depends on financial backing",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "61fce17db0279c27",
      "text": "- once money flows, companies are positioned to accelerate programs with existing innovation",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "25f1b2e7c64cdef0",
      "text": "- Most CGT work is in the development and clinical phases of workflow. Over time, asset transfer between academia to biotech, and scaling from R&D to pre-clin, to the clinic, and to commercialization will improve as setbacks expose challenges and drive standardized solutions across the industry",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b8fd3d5edafd3585",
      "text": "- Some CDMOs are still building facilities, expecting a CGT rebound once funding and regulatory clarity returns",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b78c08bb4d84b039",
      "text": "- Booth reps cited examples of pharma scooping up CGT biotechs as these targets look for an exit considering funding challenges despite promising assets",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "e4f984fdf0192fe6",
      "text": "- A rep for a large pharma we spoke to highlighted his company had completed 3-4 CGT acquisitions in the past year and is increasing internal programs and workforce here. He expects pharma will continue CGT M&A as R&D remains expensive and patent cliffs loom",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8b13bd05a2b69699",
      "text": "- Some see a shift towards allogeneic CAR-T longer-term but there are plenty of challenges around immune compatibility. Al driven quality monitoring and closed mfg. workflows are helping address challenges here.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "87b9ba9a5acf6e57",
      "text": "- Large pharma relatively resilient",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3cdba41b4f24638b",
      "text": "- Cautious given tariff/regulatory uncertainty, but willing to fund advanced workflows",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2e4f6b09b28f8c70",
      "text": "- Layoffs are helping free up budgets to support investment in automation and less labor-intensive workflows",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6ba6a12504998180",
      "text": "- Two companies specifically were called out under our coverage that are benefiting from the industry trend to more automated workflows - Repligen and Waters",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5cf940268a643d42",
      "text": "- Repligen's KrosFlo systems enable automated TFF, unlocking overnight, scalable, and hands off mfg. - noted as particularly ideal for sensitive advanced modality processing including mRNA and GT",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "08049c3377c766c4",
      "text": "- Water's BioAccord LC-MS combined with its Bioprocess Monitor App unlocks automated sample prep and real-time data/analysis- Right now, mRNA/LNP, mAbs, ADCs, and autologous CT are seeing the most benefit from automated workflows- Biogenetics and lentiviral vector is on an uptrend regarding automated workflows- LT, the full benefit towards AAV however should be unlocked once full/empty separation, release testing, delivery, and CMC expectations stabilize",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "814d84c9c43e85e0",
      "text": "- Biotech remains weak",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "596053e2de920b10",
      "text": "- Some cited demand as incrementally worse into 3Q as funding hasn't rebounded- VC funding backdrop limits ability to purchase new equipment, and customers are repurposing existing E&I wherever possible- Some biotech's are advancing one asset, then cutting R&D headcount once it moves to clinic",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "0ae83bb53ba6b15f",
      "text": "- FDA/CBER shakeups and lack of CMC standardization not helping sentiment",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "0b3edf548f42453b",
      "text": "- Some sponsors stalling investment in CGT assets until clearer guidance emerges",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "55e9634602097627",
      "text": "- Booth reps cited examples of approvals that were then pulled from the market due to underwhelming demand because of high costs to patient",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cf920a301065467e",
      "text": "- Some booths pointed to uncertainty on tariff policies as a swing factor on both their own and customer investment decisions",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "249b6825608c70d4",
      "text": "- Equipment demand sounds incrementally softer into 3Q",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f4a627fd58ae6124",
      "text": "- Automation and digital integration is attractive to customers, but overall orders have lagged and decision times are elongated as budgets across the board are still under pressure",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "38063e5a693f75fa",
      "text": "- Automation is central to both CT and GT, given that otherwise workflows are highly labor intensive with involved sensitive mfg steps",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2061999a73e06f26",
      "text": "- Resale market undercutting new E&I sales for some tools providers. A company highlighted its new strategy (as of 3Q) of buying back its instruments at a discount for the sake of reselling it with a service contract attached",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "86d45478d34bce35",
      "text": "- Onshoring not hitting the books just yet",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a217beebb70691b0",
      "text": "- Vendors noted onshoring tailwinds are all talk so far, with hopes actual construction/ equipment orders will materialize in 1-2 years",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f2e58fbba953c843",
      "text": "- MAb-related consumables seeing strong demand, while CGT resilient but not as strong as mAbs",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "ee00847dfe7b997c",
      "text": "- Volume for CGT consumables driven by later-phase/commercial work which has been relatively stable",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8d400ac8f2b2d2de",
      "text": "- Who plays where? All have their own sweet spot, so it's really about whether a customer needs flexible automation, high-volume consumables, or end-to-end biopro support",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "958aeef8f863604a",
      "text": "- RGEN and Cytiva are strong in automated workflows and modular platforms for CGT",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "71a50e09d736ad80",
      "text": "- AVTR leans more towards broad based consumables and lab supply solutions",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "14d015d85d05bcb6",
      "text": "- Merck focuses heavily on upstream/downstream biopro platforms and specialized reagents",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7c51becc1b827768",
      "text": "- On pricing, consumables are generally stable and resilient as low margins leave little room for fluctuation while E&I faces more pricing pressure due to competition, budget constraints, and larger deal sizes",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5ffd37ea23a94d07",
      "text": "Industry consolidation/facility closures benefiting larger CDMOs, but competition and overcapacity weigh on pricing power",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1e66672d14608162",
      "text": "- Larger CDMOs are picking up work from smaller facility closures. Overcapacity remains, however, and pricing continues to come down to support activity levels",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7bfade9445a5ae72",
      "text": "- In the LT and more specifically to CGT, larger players should benefit as smaller players exit, overcapacity fades, and they realize benefit from operating at scale as CMC becomes more standardized",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4ac916454d8f649a",
      "text": "- CGT innovation is here, but investment and regulatory clarity is not",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7cb3845d351cfd03",
      "text": "- Technological innovation exists and is driving material improvements in automation, yield gains, and process optimization- Variability across research, clinical, and commercial processes, high costs, lack of standardization, and weak funding prevent broad adoption- CGT sits at an inflection point, where many of the challenges are solvable but a rebound depends on regulatory clarity and funding commitment (and patience from investors/ biotech mgmt)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6a465162d21bf3ae",
      "text": "- Process intensification and PAT are unlocking continuous and automated biomanufacturing with in-line analytics - driving material improvements to mgf. timelines and eliminating downtime",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "17f2910c7413ba41",
      "text": "- Traditional microbial processes that take 2-3 weeks can now be done in 4-5 days driven by auto-induction, inline PAT tools, regression modeling, automated TFF and chromatography",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "81a79878c75ddc6e",
      "text": "- case study using this combination of tech highlighted 60% faster cycle times, 33% shorter processing, lower costs and low risk of human error",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ebb0f862fa47083c",
      "text": "- PAT tech enables real-time process controls",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4598164639a1895b",
      "text": "- automated scheduling enables overnight TFF and chromatography runs",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a6e4701246238c5c",
      "text": "- real-time release testing removes offline QA/QC delays and enables fully closed and automated workflows",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6569e0be2ef6878e",
      "text": "- Long term, these strategies will scale to GMP-compliant \"lights-out\" mfg.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "0b9e00ea32104a67",
      "text": "- Innovation and transformative science begins in academic labs, but often lacks reproducible and scalable processes- Companies routinely have to rebuild the process to meet regulatory standards, adding time, cost, and risk as assets advance down the development workflow- Investors and biotech leadership often over-promise timelines (such as claiming 8 months for IND whereas 18 months is more realistic in an optimal scenario)- this pressure drives rushed development, leading to inconsistent mfg. and failed CMC packages- Updated regulatory framework could drive standardization and align expectations- A modernized PAS 83 (CGT development guidance from the British Standards Institute that is 15yrs old) would drive clearer product development guidance, whereas now many startups take a scattershot approach to assays, endpoints, and regulatory strategy- Having consistent standards and guidance would serve as a common language across academia, industry, and investors",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "747418077a24c3f3",
      "text": "- Digital transformation is no longer optional. Scalable and connected systems are necessities- Clean and structured data is the foundation of AI-driven mfg. Poor data quality undermines everything (\"garbage in, garbage out\")- Early proof of concept wins help build trust and momentum, and the industry needs to align data scientists, LS scientists, and business mgmt.- workforce requires \"bilingual scientists\" that have both domain and data/AI expertise- AI/ML doesn't replace expert judgement and human oversight is necessary to ensure outputs make biological sense",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f457ab721e79ebe1",
      "text": "- Policy volatility and uncertainty (tariffs, taxes, regulations etc.) make LT planning unreliable, and companies are prioritizing optionally across regions- What should be insourced vs. outsourced is no longer clear. Capacity decisions have become situational and not set in stone- Post-COVID, \"just-in-case\" infrastructure is being emphasized with priority on local footprints and scalability- More specific to CGT, industry leaders suggest to not build out capacity too early and noted most early facilities have been shut down or sold. CDMOs, accelerators, and shared infrastructure is recommended until post-commercial demand is proven and sustainable",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7702a1f2f2e43229",
      "text": "What are the biggest regulatory pain points companies face in early- stage development?",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d3c023dcda36cea0",
      "text": "- Characterization challenges- Difficult for early-stage companies to achieve meaningful product characterization before Phase 3- Potency assay development is especially difficult and frequently cited as the top analytical challenge- Comparability becomes the biggest overall issue, heavily influenced by potency testing limitations",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a737cd43f4de83c3",
      "text": "- Need for more productive dialogue with FDA",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "924e276e13e4279f",
      "text": "- Companies wish to better understand FDA expectations and receive clearer guidance early on- Characterization and assay development are areas where more regulatory interaction would help",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c989650bd2ec530d",
      "text": "What challenges do companies face around phase- appropriate cGMP compliance and regulatory progression?",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8db54a68f97f8486",
      "text": "- Confusion in the field about what constitutes phase-appropriate cGMP",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9119df4ecb44fa57",
      "text": "- FDA sets a relatively low bar for IND acceptance to enable development, but this is often misinterpreted as sufficient for later stages- Companies may deprioritize key development activities (like potency assays) because of early FDA flexibility- This creates problems during pivotal trials or BLA preparation when more robust standards apply",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "e8b183a21df90301",
      "text": "- Lack of preparation for BLA submission",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "34f0414f5a4874d7",
      "text": "- There's less clear guidance for BLA readiness compared to IND submissions- Companies often rely on people with mAb inspection experience, which doesn't translate well to newer modalities like CGT- Facility inspections have caused major delays for recent BLAs, highlighting this gap",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "e4cf87d0ed11342f",
      "text": "What do companies need to better understand about assay development and process control?",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "53bfc121d2c99ff5",
      "text": "- Critical quality attributes (CQAs) and process control systems:- Many companies lack understanding of how to identify and control CQAs and critical process parameters- Poorly developed process control strategies remain a recurring issue across projects",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "14ac04b088eb0b1d",
      "text": "- Benefits of communicating long-term assay plans to FDA- Sponsors are viewed more favorably when they share their long-term assay strategies during early IND discussions- Even if assays aren't finalized, showing a roadmap builds confidence with the agency",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7136efa7b2128713",
      "text": "- QTPP is underutilized by early-stage companies- Many startups are unaware that building a QTPP early can guide development more effectively- Not doing so results in unclear development targets and suboptimal alignment with regulatory needs- Lack of QTPP and TPP planning is more an issue of awareness than difficulty- These aren't technically hard to do, but are often viewed as lower priority due to resource constraints",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "7ca666353d9da41f",
      "text": "- BiMo (Bioresearch Monitoring) inspections focus on GCP compliance- BiMo operates under the Office of Compliance, separate from the product review office at FDA- Inspections are typically \"for cause\" to ensure proper conduct of clinical trials- Unclear future direction of BiMo oversight- While not highly aggressive now, there is ongoing activity and increased scrutiny on clinical operations- Companies need robust internal systems to ensure compliance, especially when working with CROs",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "efd130cefade0199",
      "text": "- Translation from academia to industry remains a major hurdle- NIH and academic research generate many transformative technologies, but the transition to commercial development is weak- Many early-stage decisions (indication selection, manufacturing, regulatory strategy) are not thoroughly vetted- Misalignment in indication choice and development strategy- Companies sometimes choose suboptimal indications that are less favorable from a commercial or clinical perspective",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "768066bd19e073f7",
      "text": "- Academic labs are not trained in product development- Their role is scientific discovery, not scalable or consistent manufacturing- Pharma struggles with academic variability- Cited example: CART-19 at Penn had inconsistent manufacturing runs.- Academic operating procedures often lack the reproducibility pharma expects- Companies often need to recreate manufacturing processes post-tech transfer:- There's a widespread need to decode and re-engineer academic processes for regulatory use",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "88f91b764845c80b",
      "text": "- Potency assay development, process understanding, and manufacturing knowledge require sustained investment- Companies often miscommunicate timelines to investors, claiming products can be developed in 3-4 years- Unrealistic timelines lead to incomplete CMC packages and potential clinical or commercial failure- Emphasis on what cGMPs are meant to do- cGMPs are not just regulatory hurdles - they ensure consistent and reproducible manufacturing- Failures in cGMP execution can sink assets during approval or commercial scale-up- Product knowledge drives cost control- Deep understanding enables comparability strategies and manufacturing efficiencies that reduce cost",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "7f1d6abf30b8a448",
      "text": "- Lack of transparency in timelines and risks- Product development is often rushed due to patient advocacy or investor pressure- Rushed development results in inconsistent manufacturing and potential loss of company viability- Greater education needed for investors and founders- Investors must understand development timelines aren't a function of effort, but of complexity- Founders often don't realize what it takes to go from academic proof-of-concept to a regulated therapy",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "10210bc7f9eaa849",
      "text": "- Need for clearer developmental guidance- Many startups take a scattershot approach to development, lacking clear rationale for marker selection, assay endpoints, etc.- Panel suggests an update to PAS 83 (British Standards Institute guide)- Originally written \\(\\sim 15\\) years ago for CT development in U.K./U.S.- This process guide could be modernized and adapted to current industry needs - helping align efforts with regulatory and commercial expectations",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a003c526a10b69a7",
      "text": "- Gaps exist across all levels- Academic founders: focus remains on lab work and research, with little guidance given towards company development- Biotech management: often unfamiliar with complexities of development and overpromise to their investors- Common example: CEO expecting an IND in 8 months when 18 months is more realistic, even under optimal conditions- Investors: frequently set unrealistic expectations, not due to deception but due to misunderstanding",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "2b527c6bdb527a1a",
      "text": "- Persistent global ambiguity complicates strategic planning in manufacturing- Rather than predicting policy changes, focus should be on providing optionality for pharma to adapt across multiple scenarios- Amgen is investing in manufacturing capacity in multiple geographies including new builds in North Carolina and Ohio, as well as expansions at brownfield sites in Rhode Island, Puerto Rico, and Ireland- Shift in mindset around internal vs. external capacity:- Previously rigid distinctions between what should be insourced or outsourced are now being re-evaluated- Flexibility is needed in deciding whether to internalize or externalize based on situational advantages",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "2dda2472b19b4cb0",
      "text": "- Shift from U.S.-centered to globalized biopharma manufacturing- The 1990s model of \"offshore\" as Puerto Rico or Singapore is outdated- Current mfg. includes China, Taiwan, Korea",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e390451b633b1feb",
      "text": "- Despite geopolitical tensions and supply chain reshuffling, globalization is here to stay due to inherent value creation",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3305dc7244fe02aa",
      "text": "- IPO expectations in 2018 were \\(200–500M\\); today, even top IPOs underperform- High-risk, uncertain ROI in CGT necessitates a new development paradigm",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c8b2887d8060e5b3",
      "text": "- Accelerator models are designed to support early-stage CGT development with a scalable and GMP-compliant framework",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "69c55132c635c8c9",
      "text": "- Emphasis on preventing common CGT pitfalls",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "e94f0058df502a46",
      "text": "- Many early-stage therapies reach human trials with processes that can't scale to phase 2 or 3",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5189fd5bab7f9fbc",
      "text": "- Focus on building \"just-in-case\" infrastructure post-COVID, emphasizing resilient and local manufacturing capabilities",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f31eec1a84c8827c",
      "text": "- Goal is to provide global access to efficient drug development, including academic and biotech teams",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b61048f34f543136",
      "text": "- Industry seeing exponential growth in modality complexity (e.g.: AI-designed proteins, CAR-T, AAVs)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5d4c0e2967056603",
      "text": "- Mfg. complexity is rising alongside scientific elegance",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "7c405898a5ca8001",
      "text": "- Mfg. capabilities must become a competitive advantage:",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6bc26628fd454ed5",
      "text": "- Involves integration of process development, quality, supply chain, and engineering",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "aa47514a74407e5b",
      "text": "- Focus on manufacturability from the start of process development",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9062530ab5e1b325",
      "text": "- Process intensification and smaller footprints are key to cost control",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3a0a5b0148021c7a",
      "text": "- Speed to clinic/market is emphasized as a differentiator",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "31e7d3f5bb368a08",
      "text": "- Significant cost inefficiencies in commercial autologous cell therapies:",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5583c65fa2885151",
      "text": "- \\(\\) 400K-\\$ 500K per treatment due to labor intensity and expensive raw materials (e.g.: magnetic beads)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "90f054bc6fdfda95",
      "text": "- Facilities for several thousand patients can require 1,000-1,500 employees",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4229da5b76b0ebb7",
      "text": "- Cost reduction must come from automation and reducing dependency on high-cost suppliers",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "6342e08527a36f6d",
      "text": "- Need to transform from ex-vivo to in-vivo approaches to reduce complexity and costs",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "562010f2f301fcf8",
      "text": "- Building flexible, digitally connected facilities is key in greenfield projects- Digital design allows for data generation and AI-driven predictive modeling- Digitization eliminates paper, enables real-time monitoring, and supports continuous improvement- Evolving workforce demands cross-functional skillsets (biology + informatics + engineering)- Emphasis on leadership-led digital transformation and upskilling at all levels",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "add9551f90bec39f",
      "text": "- Strong caution against early-stage companies building manufacturing before demand is proven- Most CT companies that built facilities post-2017 later shut down or sold them by now- Recommendation: wait 2-4 years post-commercialization before investing in facility- Early capital is better spent on product development, not infrastructure- CDMO and shared infrastructure models (like accelerators) provide viable alternatives",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7aa22160458eecb0",
      "text": "- Policy inconsistency (shifting regulations and leadership shakeups) poses risk to both manufacturers and drug developers. Investors and drug sponsors need clarity and visibility- In Europe, innovation exists but translation to clinical development is weak- Europe lags behind the U.S. and Asia in clinical activity due to fragmented access, conservative VCs, and regulatory challenges",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "33c30dab2789c79b",
      "text": "- Mfg. optimization could benefit from lessons in other industries (e.g., food, high-throughput scheduling)- Biotech historically viewed itself as unique, but many best practices in ops, scheduling, and digitization are transferable",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "6783150df8b94c00",
      "text": "- U.S. competitiveness depends on innovation in tech, workforce productivity, and work ethic.- TSMC's struggle in the U.S. (vs. Taiwan) cited as a cautionary tale—talent and work ethic must match investment- U.S. still leads in CGT technology, particularly in next-gen platforms (e.g., in vivo therapies) - so CGT (as opposed to other modalities) would likely be U.S.-based- Fill-finish is likely to be reshored due to automation potential",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "5ff3b3939848baf3",
      "text": "- Mfg. for rare diseases remains cost-prohibitive due to small batch sizes and high material costs- Suggested approach:    \n- Use RNA-based platforms for early proof-of-concept to attract funding    \n- Avoid early capex-heavy strategies    \n- Accelerators can provide phase 1-3 manufacturing support at cost, but even then costs remain high    \n- LT viability depends on transforming vector manufacturing (e.g.: cheaper AAV, reduced reliance on plasmids)    \n- Platform-based strategies may help—aggregating rare diseases to scale shared infrastructure.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "313b741b68855a6e",
      "text": "Case study example of what Sanofi found effective",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f8ae942c5e1c6164",
      "text": "- Traditional microbial drug substance processes take 2-3 weeks    \n- Sanofi reduced process time to 4-5 days using value stream mapping and automation    \n- Goal: eliminate hidden waste (manual interventions, offline assays, downtime)    \n- Strategy: introduce auto-induction, inline analytics, real-time control, and overnight continuous operations.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "9390d182d7052b07",
      "text": "- Challenge: Manual induction and waiting periods create inefficiencies- Solution:    \n- Installed Hamilton density probes (optical density + raw transmission/reflection data)    \n- Applied regression modeling for continuous biomass measurement    \n- Integrated with process control software that enables auto-induction at any time",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "554151303f5dbea3",
      "text": "- Eliminated need for operator intervention during induction    \n- Enabled hands-free fermentation from inoculation to harvest",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "9ed3af8b6d5196ed",
      "text": "- Previously limited to daytime due to offline assays and safety concerns    \n- Offline protein assays caused delays",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "7b5be708abc49bc0",
      "text": "- Identified safe operating conditions for TFF- Implemented overnight automated TFF runs- RGEN's automation platforms were highlighted as an example of a trusted system for safe overnight TFF operation",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1fa8899d9f75c3fa",
      "text": "- In-line protein quantification:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "7a91bee759f6ecf5",
      "text": "- Adopted mid-infrared spectroscopy- Regression models validated linear protein concentration detection- Enabled real-time bulk protein measurement, replacing offline assays",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "9c2597ba1d210c7b",
      "text": "- Chromatography bottleneck:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "b56608ed31d68cbf",
      "text": "- Single column runs \\(= 7 - 8\\) hrs \\(+7 - 8\\) hrs downtime- Needed manual buffer conditioning between columns",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "69cefdab78bbee27",
      "text": "- Added inline conditioning and fraction collection- Queued back-to-back column runs overnight (e.g., Column 1 \\(\\rightarrow\\) buffer \\(\\rightarrow\\) Column 2)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "8de1e8f55d57d064",
      "text": "- Reduced two-column sequence from \\(\\sim 2\\) days to 16 hours (one night).- Achieved \\(50\\%\\) reduction in operating time",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1d49e6a4e02426ab",
      "text": "- Final TFF & Concentration:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "1804cefc9d7fdb56",
      "text": "- Integrated inline UV absorbance sensors- Both Repligen and Sartorius TFF systems cited as compatible automated platforms for final drug substance concentration- Real-time protein concentration measurement prevents over-concentration, aggregation, contamination",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d7a4c516b2a95d6f",
      "text": "- Removed offline protein assays- Closed, automated final drug substance prep- Overall: \\(33\\%\\) shorter processing time, zero downtime, zero offline samples",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "89fdedb9c49c08e0",
      "text": "Auto- induction (AI- driven, model- based)  - Inline PAT tools: biomass probes, mid- IR spectroscopy, inline UV  - Automated scheduling & queuing of chromatography and TFF  - Real- time release testing eliminates waiting on offline QC",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e1cc1ab66211887f",
      "text": "- AI platforms used for regression modeling and control  - Looping software handles real-time decision-making and pump control  - Presenter highlighted Repligen and Sartorius systems serve as the backbone for closed, automated PAT-enabled operations in both midstream and downstream",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "73d696e7ce4702bc",
      "text": "- Reduced microbial drug substance process from 2-3 weeks \\(\\rightarrow\\) 4-5 days.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "522630386f5186ec",
      "text": "- 60% faster cycle time  \n- Zero downtime, zero offline assays  \n- Lower cost of goods",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "742946fc65564bfb",
      "text": "- Faster development \\(\\rightarrow\\) frees resources for deeper studies  \n- Process intensification applicable at development scale (≤5 L) and pilot scale (2,200 L)",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "f1b5bff8b536267d",
      "text": "- Move toward automation, real-time release, and lights-out manufacturing  \n- Repligen & Sartorius platforms positioned as key enablers for scaling this model into larger, GMP-compliant biomanufacturing",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "f0bda95a969840d5",
      "text": "- Foundational Principles",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "d78105cb20d25f03",
      "text": "- Not optional: Digital transformation is now a necessity, not a choice",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "ba47d3a5fcceab67",
      "text": "- Focus on infrastructure:",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "fd362547af173f83",
      "text": "- Build scalable, connected systems  \n- Ensure data accessibility and integration across platforms",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "fa5a15b18f4a5025",
      "text": "- Data as the foundation:",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "1944ffd092918f5b",
      "text": "- Clean, well-structured data is essential  \n- \"Garbage in, garbage out\" still applies — poor data quality undermines analytics",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "981c76deeeab02a9",
      "text": "- Good practices for data management must be standardized",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "615b6aeb8f4d9350",
      "text": "- Questions organizations must ask:",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "56465bf7192551ab",
      "text": "- Has the vendor enabled data extraction in a scalable way?- Can new instruments/systems be integrated quickly without major effort?",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "5e3643849d27f626",
      "text": "- Importance of traceability and interoperability:",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "874bb26eb6e3c4bd",
      "text": "- Integration across labs and systems reduces redundancy",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "5df14f62a71339bd",
      "text": "- Early use cases (e.g.: automating system-to-system data flows) demonstrate efficiency gains",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "3e1b8c113a086fab",
      "text": "- Identifying early adopters vs. resisters in labs and functions- Change management is as important as technology",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "bc7889329405a109",
      "text": "- Cross-functional teams (IT, scientists, business owners) often have competing priorities- Incremental adoption with POC (proof of concept) use cases builds trust",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "f5af151825b70250",
      "text": "- Cannot pause drug development while experimenting with digital solutions- Must balance disruption with patient and business needs",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "fe4500b66f491341",
      "text": "- Models often produce spurious correlations- Human expertise is required to validate whether outputs make biological or chemical sense",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "02a61563108249cd",
      "text": "- Use simulations and structured governance to validate outputs- Transparency in model design and assumptions builds credibility",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9d01a242d23a6569",
      "text": "- Analytics compared to \"nuclear weapons\" — powerful but risky if mishandled- Need for \"bilingual scientists\": people trained in both domain science (biology/chemistry) and data/AI methods",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "2287ee78f1be2e85",
      "text": "- Digital twins, simulations, and mechanistic models:- Enable faster process development and optimization- Reduce reliance on repetitive large-scale experiments- Success cases:- mRNA process modeling (heat transfer, chemistry-driven) \\(\\rightarrow\\) reliable, reproducible scale-up- System integration enabling faster preparation and automation across bioreactors",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "7c788df45e553a9f",
      "text": "- Digital literacy gap - Many scientists lack strong AI/data training",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "31dacad93610f041",
      "text": "- Systematic and consistent global training programs- Mandatory training initiatives- Build basic literacy in AI concepts, digital workflows, and data quality principles",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "b94d263bbe9ca08c",
      "text": "- Change must be actively managed:",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "4e70ef43b9b67e2d",
      "text": "- Requires clear communication, budget allocation, and reprioritization of projects- Early engagement of stakeholders is key- Define 4-5 clear use cases once infrastructure is in place to show business value- Adoption depends on business impact: teams will embrace solutions that accelerate or de-risk their work",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "922aa19c841a5028",
      "text": "- Integration of offline and online models:- Currently, many models run offline- Goal: dynamic integration where models directly adjust process controls in real time- Interpretable AI: Need for tools that produce insights understandable by both data scientists and biologists/chemists- Digital maturity timeline:- Current stage = incremental improvements and pilots- Next 5 years = more dynamic, model-driven process controls and broader adoption",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "0a9a0528e52c6949",
      "text": "Analyze Media, Titer, Product Attributes",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "ae7dce36766e18ba",
      "text": "- Samples often sent to core/contract labs which can take weeks/months- Data not actionable within the cell culture time frame (-2 weeks)- Inefficient process development — limited ability to adjust during run",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "b8e33d8c681dd060",
      "text": "- Simplified, automated high-resolution LC-MS deployed next to bioreactor- Enables faster turnaround (days \\(\\rightarrow\\) hours), more data, and real-time statistical analysis- Integrated automation: automatic sample introduction and simplified workflows (BioAccord LC-MS + monitoring software)- Product quality decision-making- Correlates titer with purity/other quality attributes to avoid misleading titer-only decisions",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "ee6d336a01ebe332",
      "text": "- Patrol UPLC system- Designed for continuous/semi-continuous monitoring of CQAs (critical quality attributes)- Onboard automation: dilution, calibration, sample prep- GMP-ready: data compliance, connectivity via OPC-UA",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "feba26e0a76a52d4",
      "text": "- Real-time multi-angle light scattering (MALS)- Traditionally paired with SEC (downstream analytics)- Modified to enable inline/online deployment, enabling fast and direct measurement of product attributes- What it measures- Molar mass, size, particle concentration- Aggregation levels, payload conjugation ratios- Applicable across biologics and modalities- Benefits- Captures average product attributes in near real-time without relying solely on complex models",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "92439008bd0b6fe0",
      "text": "- Supports process understanding: resin selection, buffer optimization, depth filtration, aggregation tracking- Enables endpoint control and pooling decisions during DS purification",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "29c39d47a80d95e4",
      "text": "- Sensitivity at low concentrations (early phase harvest)- Need methods that span entire campaign without constant recalibration",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "655b0f1410e256bf",
      "text": "- High sensitivity SEC/Protein A columns- SEC = Selenocysteine, a naturally occurring amino acid- Detects low-level titer and impurities earlier- Applicable to both large harvest samples and small-volume culture supernatants- Capabilities- Quantify titer along with high/low molecular weight species- Compare experimental vs. control conditions- Multiple modes available:  - SEC (Protein A + SEC) = simple workflows  - HIC (hydrophobic interaction) = alternative resolution for aggregates- Outcome  - Allows earlier, faster process decisions with fewer recalibrations  - Better resolution of low-level species and improved process monitoring",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "59581a0a5c266a70",
      "text": "- Particle analysis with Aura (Halo Labs, acq. by WAT)- Based on Background Membrane Imaging (BMI)- Captures subvisible and visible particles in solid form- high contrast and detection sensitivity- Use cases- Protein biologics, gene therapies, cell therapy suspensions- Helps assess manufacturability, stability, and long-term product quality",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "a99d97f62ef8fe29",
      "text": "And how Sangamo, a gene editing biotech, is addressing them",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "e80faa600aa80a64",
      "text": "- Gene editing involves a toolbox of technologies- Traditional tools include base editors and nucleases- Sangamo's core focus is on epigenetic editors enabling gene activation/repression without DNA breaks- Their Modular Integrase (MINT) platform adds non-breaking, payload-flexible capabilities",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "981ef353b3742a90",
      "text": "- Safety and rational design",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "30704be3b5f5fb93",
      "text": "- Significant regulatory and scientific focus on off-target effects and long-term unknown risks",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "f82cb4a2b9bf9ab0",
      "text": "- Sangamo's zinc finger platform has been optimized to only allow functional left-right pairings to mitigate risk",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "09d858c423cbe777",
      "text": "- MINT platform overview",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "40c0288e92c25897",
      "text": "- Works analogously to electrical shunting: redirects transcription/read sequence without breaking DNA",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2aaee86ca03c51d9",
      "text": "- Can deliver payloads >10kb- No reliance on cell's DNA repair- No strand breaks, low error rate- Highly specific targeting- Applicable to multiple variants of a disease with a single therapeutic",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "5cb6497274a5afbe",
      "text": "- AAV delivery remains a critical challenge, especially for CNS- Liver and cardiac tissues are relatively accessible- Ocular and CNS are promising but difficult due to barriers such as the blood-brain barrier (BBB)",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "7a1346053b7ce490",
      "text": "- Sangamo's SIFTER platform",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "3e23ef2525f88b08",
      "text": "- Screens capsid libraries for tissue-specific AAV tropism- Identified BBB-penetrant capsid variant \"Stack BBB\"- Demonstrates high and even distribution across all brain regions- Strong CNS penetration with minimal off-targeting",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2c7a00997de97f42",
      "text": "- Comparative efficacy- Stack BBB outperforms AAV in brain region targeting- Effective for applications requiring broad and specific CNS delivery",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "aad24e2b65f30a52",
      "text": "- Prion disease characteristics- Fatal, rapid progression (~4-5 months post-onset)- Includes sporadic, inherited, and acquired forms- Sangamo strategy- Combines Stack BBB with epigenetic repressors- Micrograph results show widespread repression of prion protein in NHPs",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "a6a097f2f6c78ca6",
      "text": "- Preclinical efficacy",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "67d7cb1003c33cff",
      "text": "- Mouse model- Repressor administered at day 100 post-infection- Control mice died \\(\\sim 50\\) days post-treatment- Dosed mice showed survival increase, with high-dose achieving \\(>50\\%\\) LT survival through the life of the mice- NHP correlation- Tissue distribution aligns with mouse data, supporting potential human translation",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "e22d880be3a1cb89",
      "text": "- Key challenges in scaling gene therapies:- Lack of standardization in cell culture and purification processes.- Current methods vary, including... micelles, roller bottles, suspension cells, non-293 cell lines- Aggregation challenges remain, with SEC (size exclusion chromatography) data offering limited insight",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "9e1fbe0de5eced51",
      "text": "- Use of platform analytics to improve scalability and reproducibility- Focus on excipients and platform-based manufacturing approaches",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "1b0c464e63ad763a",
      "text": "- Safety tightly linked to design and delivery, and we need to understand capsid delivery and how it works en-route",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "c1a75c135e7fd6a6",
      "text": "- Comparative imaging of mouse and non-human primate brains shows consistent capsid distribution- Sangamo's delivery specificity is confirmed via identification of \"Receptor One\", which confirms mechanism of capsid uptake- Reduces safety uncertainty by linking delivery vector to a known biological target",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "fa096774eb762cc5",
      "text": "- Neuropathic pain: major contributor to opioid epidemic- Traditional pain inhibitors are non-specific; gene editing offers more targeted approach- Sangamo's epigenetic strategy:- Targets NaV1.7 and NaV1.8 in DRG neurons- Repression can be titrated for balance between pain relief and sensory function.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "67a5db950d2b4611",
      "text": "- Key challenge in pain trials: high subjectivity and need for sham-controlled design",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "d0cd8917e5606a7f",
      "text": "I, Luke Sergott, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "a1a10f7b605563d6",
      "text": "In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "85b2e909bae71395",
      "text": "Barclays may also re- distribute equity research reports produced by third- party research providers that contain recommendations that differ from and/or conflict with those published by Barclays' Equity Research Department.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "6827179facfdfb5a",
      "text": "Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "57fa4c4d569acd6e",
      "text": "This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of Canadian Investment Regulatory Organization (www.ciro.ca), and a Member of the Canadian Investor Protection Fund (CIPF).",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "033f4990aa2db43a",
      "text": "This communication is directed at persons who are a \"Wholesale Client\" as defined by the Australian Corporations Act 2001.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "a37806380d2efd5f",
      "text": "Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 (\"Advisory Law\"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "636315d637ddda97",
      "text": "as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "c91441da4672dad8",
      "text": "Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non- Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "170b24824022f6df",
      "text": "Sustainable Investing Related Research: There is currently no globally accepted framework or definition (legal, regulatory or otherwise) of, nor market consensus as to what constitutes a 'sustainable', 'ESG', 'green', 'climate- friendly' or an equivalent company, investment, strategy or consideration or what precise attributes are required to be eligible to be categorised by such terms. This means there are different ways to evaluate a company or an investment and so different values may be placed on certain sustainability credentials as well as adverse ESG- related impacts of companies and ESG controversies. The evolving nature of sustainable investing considerations, models and methodologies means it can be challenging to definitively and universally classify a company or investment under a sustainable investing label and there may be areas where such companies and investments could improve or where adverse ESG- related impacts or ESG controversies exist. The evolving nature of sustainable finance related regulations and the development of jurisdiction- specific regulatory criteria also means that there is likely to be a degree of divergence as to the interpretation of such terms in the market. We expect industry guidance, market practice, and regulations in this field to continue to evolve.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "374b7d308f3f9313",
      "text": "Any information, data, image, or other content including from a third party source contained, referred to herein or used for whatsoever purpose by Barclays or a third party (\"Information\"), in relation to any actual or potential 'ESG', 'sustainable' or equivalent objective, issue, factor or consideration is not intended to be relied upon for ESG or sustainability classification, regulatory regime or industry initiative purposes (\"ESG Regimes\"), unless otherwise stated. Nothing in these materials, including any images included therein, is intended to convey, suggest or indicate that Barclays considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG or sustainability classification, label or similar standards that may exist under ESG Regimes. Barclays has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "f1a911cda108dd77",
      "text": "IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax- related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.",
      "page": 24,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "acfb38cd6e11f1c1",
      "name": "Accelerating Biopro",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4a0d39d6e8ef277c",
      "name": "Advanced Control",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "26541a99d9d9a73a",
      "name": "Advanced Modeling",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1cf412485ca8530",
      "name": "Advisory Law",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d74f5b8a4feb8851",
      "name": "Allogeneic CAR",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "facedae141187a9f",
      "name": "Australian Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "86a4d8c601b17545",
      "name": "Autologous Cell",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a888e086f4687d35",
      "name": "Background Membrane",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "46a2e39eafb9f3ae",
      "name": "Barclays Capital",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4d2d57430a6b5e51",
      "name": "Barclays Equity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1d3bfaf58595d0a",
      "name": "Barclays Israeli",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1948c309aa8e8d88",
      "name": "Bio Innovation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9ebde27d0192b9bc",
      "name": "BioAccord LC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "eba139081988070b",
      "name": "BioResolve Columns",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "eab73d13841eb0d3",
      "name": "Bioprocess Monitor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "51632115852d3f16",
      "name": "Bioprocessing Summit",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "df7e8d341d1570f9",
      "name": "Bioresearch Monitoring",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3bd0feeb7a5c7cb1",
      "name": "Boston Edition",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "43eaad71f3b92310",
      "name": "Both Repligen",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d862e6cab743d1b1",
      "name": "British Standards",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "3e72cccff81c13c5",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "modeling, automated TFF and chromatography - case study using this combination of tech highlighted 60% faster cycle times, 33% shorter processing, lower costs and low risk of human error - PAT tech en",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "731c2b110601528c",
        "value": 0.33,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "and chromatography - case study using this combination of tech highlighted 60% faster cycle times, 33% shorter processing, lower costs and low risk of human error - PAT tech enables real-time process ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d6bcfcf6bdd97fee",
        "value": 500000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "l Therapy - Significant cost inefficiencies in commercial autologous cell therapies: - \\(\\) 400K-\\$ 500K per treatment due to labor intensity and expensive raw materials (e.g.: magnetic beads) - Facil",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "49d581e44bd29c09",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d microbial drug substance process from 2-3 weeks \\(\\rightarrow\\) 4-5 days. - Efficiency gains: - 60% faster cycle time - Zero downtime, zero offline assays - Lower cost of goods - Benefits: - Fa",
        "provenance": {
          "page": 13
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 0,
      "tables_count": 0,
      "numerical_data_count": 4,
      "passages_count": 197,
      "entities_count": 20
    }
  }
}